Genentech, Inc. (NYSE:DNA) invites investors, the media and the general public to listen to a webcast of a discussion following the Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee (PADAC) review of the Biologics License Application for Xolair (omalizumab).

The webcast will begin at 3:45pm Pacific Time on May 15, 2003. The live webcast can be accessed by going to Genentech's website at http://www.gene.com and will be archived and available for replay until 5:00pm Pacific Time on May 22, 2003.

An audio replay of the webcast will be available beginning at 6:45pm Pacific Time on May 15, 2003 and ending at 5:00pm Pacific Time on May 22, 2003. Access telephone numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); passcode number is 490586.

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Fifteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes ten biotechnology products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For press releases and additional information about the company, please visit http://www.gene.com.